IPCA Laboratories Limited — Q1 FY26 earnings call

Call held 12 Aug 2025

Management summary

Ipca Labs reported a mixed Q1 FY26 with strong standalone and consolidated net profit growth, driven by robust domestic and export performance. However, consolidated EBITDA margins saw a slight decline, primarily due to underperformance and one-time provisions within the Unichem subsidiary. The company revised its full-year consolidated EBITDA margin improvement guidance downwards, while maintaining topline growth targets.

Highlights

  • Standalone net profit increased by 26% to Rs. 262 crores in Q1 FY26.

  • Consolidated net profit grew by 18% to Rs. 234 crores in Q1 FY26.

  • Domestic business grew by 10% in Q1 FY26.

  • Export branded formulation business grew by 10% to Rs. 124 crores.

  • Export generic business grew by 15% to Rs. 326 crores.

  • API business grew by 12%.

Concerns

  • Consolidated EBITDA margin marginally declined to 18.39% in Q1 FY26 from 18.52% in Q1 FY25.

  • Unichem's gross margin declined due to market share loss in profitable US products and business decline in Asia (Myanmar) and Brazil markets.

  • Unichem incurred an additional provision of Rs. 12 crores due to Euro currency fluctuation for an EU penalty and Rs. 10 crores for Ireland facility closure.

  • India's cardiovascular therapy business grew only 8%, below expectations, due to reorganization and manpower recruitment.

  • Onyx Scientific reported a loss of 300,000 sterling pound in Q1 FY26 due to reduced business from multinational companies.

Key financials

  1. Standalone Net Profit ₹262 Cr +26%YoY
  2. Consolidated Net Profit ₹234 Cr +18%YoY
  3. Standalone EBITDA Margin 23.8%
  4. Consolidated EBITDA Margin 18.4%

What they filed

Q1 FY27: revenue up 21.3%, net profit up 42.4% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,811 1,663 1,638 1,747 1,930 +7%1,845 +11%1,814 +11%2,119 +21%
EBITDA402 411 359 407 465 +16%477 +16%431 +20%578 +42%
Net profit244 268 -65 262 305 +25%303 +13%262 +503%373 +42%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Domestic Business
    10% Growth
  • Export Branded Formulation
    ₹124 Cr Revenue10% Growth
  • Export Generic Business
    ₹326 Cr Revenue15% Growth
  • API Business
    12% Growth
  • Unichem US Business
    12% Growth
  • Unichem Consolidated
    9% Growth
  • Unichem European Business
    ₹36 Cr Revenue37% Growth

Guidance & targets

Revenue

  • Consolidated Topline Growth Revenue · FY26 · High confidence 9%-10%
    our guidance for the consolidated number was around 9%-10% overall growth and overall margin increased by around 1% EBITDA margin... topline would remain in the similar kind of range

    — A. K. Jain

  • Ipca Standalone US Business Revenue Revenue · current financial year · High confidence $15-$16 million
    I think that could translate around $15-$16 million kind of business

    — A. K. Jain

Margin

  • Consolidated EBITDA Margin Improvement Margin · FY26 · High confidence 75 bps

    Previously 100 bps → 75 bps

    So, did I hear it right that you are expecting 19% growth in FY '26 and console EBITDA margin to improve by 75 basis points versus 1% basis points that was the earlier guidance? A. K. Jain: Yes, that is correct.

    — A. K. Jain

  • Standalone EBITDA Margin Improvement Margin · FY26 · High confidence 1.5%
    Our guidance was also to increase overall standalone margin by almost around 1.5%.

    — A. K. Jain

Product Launches

  • Ipca Standalone US Product Launches Product Launches · current financial year · High confidence 4-5 products
    Another 4-5 products also should get launched during the current financial year.

    — Harish Kamath

  • Ipca Standalone US Product Launches (Annual) Product Launches · every year, going forward · High confidence 5-6 products
    But going forward, every year, 5-6 Ipca products will go on getting launched in the US market.

    — Harish Kamath

Headcount

  • Field Force Additions Headcount · every year · Medium confidence 3%-4%
    Maybe around 3%-4% field additions will keep on happening every year.

    — A. K. Jain

Profitability

  • Subsidiaries Meaningful Contribution Profitability · 2-3 years · Medium confidence 2-3 years
    I think 2-3 years period is a good, 2 years period is a good number to see that. We scale up all these kind of subsidiaries.

    — A. K. Jain

What to watch in Q2 FY26

Unichem's recovery in US, Asia, and Brazil markets

Coming quarters
Current US market share loss in 4 products, Asia business down to Rs. 8cr, Brazil down to Rs. 14cr
Target Recovery in market share and business growth in these regions

Why it matters

Unichem's underperformance significantly impacted consolidated margins in Q1.

Let us say, overall, as far as Unichem is also concerned, we are hopeful that there will be recovery. Even on the products there in the 1st Quarter, we have lost some kind of market share. But we expect those kinds of recoveries to happen in the coming quarters.

Risks & concerns

  • Unichem's declining gross margin and overall profitability.

    high

    Unichem's gross margin declined due to market share loss in 4 major US products, business decline in Asia (Myanmar from Rs. 23cr to Rs. 8cr) and Brazil (from Rs. 21cr to Rs. 14cr), and one-time provisions of Rs. 12cr (Euro fluctuation for EU penalty) and Rs. 10cr (Ireland facility closure).

    Management acknowledged

  • Continued losses and underperformance of key subsidiaries (Onyx Scientific, Pisgah).

    high

    Onyx Scientific reported a loss of 300,000 sterling pound in Q1 FY26 due to reduced project business from multinational companies. Pisgah continues to incur losses, though in line with last year. New German subsidiary may also incur initial losses.

    Management acknowledged

  • Underperformance of India's cardiovascular therapy business.

    medium

    Cardiovascular therapy growth was around 8%, below expectations, due to reorganization and recruitment challenges for two new marketing divisions.

    Management acknowledged

  • Highly competitive and challenging UK market.

    medium

    UK market faced excess inventory, offloading of short-dated expiries, product prices coming down, and some products selling below cost, making it a tough scenario in Q1 FY26.

    Management acknowledged

Q&A highlights

6 direct
Unichem's Q1 gross margin decline, overhead expenses, and impact on consolidated EBITDA margin. Direct
As far as Unichem is concerned, Unichem US business has grown by around 12% and overall, the Unichem business has grown, consolidated number is around 9% growth. Some business has declined in their Asia and African markets, more particularly Asia market because of issue ongoing in Myanmar. From Rs. 23 crores, the business has come down to around Rs. 8 crores... And there are almost around Rs. 10 crores additional expenditure debited to the P&L account because of closer announce at the facility which they have in Ireland.

Explains the key drivers behind Unichem's underperformance and the drag on consolidated margins, including specific one-time provisions.

Asked by Saion Mukherjee (Nomura)

India business growth being slower than past and demand environment, specifically cardiovascular therapy. Direct
In the India business, let us say most therapies we have done well, except cardiovascular therapy, because in this therapy, we have done the reorganization of business... The growth has come down to around 8% in this particular quarter. But there faster recovery is happening and we are hopeful that we will do much better than we were doing earlier as far as cardiovascular therapies are concerned.

Identifies a specific underperforming segment in the domestic market and the reasons for it, with an expectation of recovery.

Asked by Saion Mukherjee (Nomura)

Clarification on Unichem's Rs. 12 crores currency fluctuation and Rs. 10 crores additional impact. Direct
It is part of the other expenses. What happened, there was a 14 million EU penalty for which we provided in the last financial year, 14 million Euro... So, that is the reason we have to make additional provision of another Rs. 12 crores... Ireland, we are closing down that facility. So, the amount Rs. 8-Rs. 10 crores is all redundancy amount which we have to pay to employees who are going out.

Provides precise details on the nature and amounts of the one-time expenses impacting Unichem's profitability.

Asked by Saion Mukherjee (Nomura)

Performance of subsidiaries (Onyx Scientific, Pisgah) and their timeline for meaningful contribution. Direct
Only one subsidiary which was always doing better, Onyx Scientific. This year, they have not done that well because all these not necessary expenses are being reduced by all multinational companies... Pisgah continues to be incurring losses, but in line with what it was incurring last year. The injectable project is ongoing and should get commercially ready by second half of this financial year... I think 2-3 years period is a good, 2 years period is a good number to see that. We scale up all these kind of subsidiaries.

Highlights the continued losses and challenges in key subsidiaries and provides a long-term timeline for their expected turnaround and contribution.

Asked by Surya Narayan Patra (Phillip Capital)

Revision of consolidated EBITDA margin guidance for FY26. Direct
So, did I hear it right that you are expecting 19% growth in FY '26 and console EBITDA margin to improve by 75 basis points versus 1% basis points that was the earlier guidance? A. K. Jain: Yes, that is correct.

Confirms a downward revision in the consolidated EBITDA margin improvement target for the full year, indicating increased pressure.

Asked by Nikhil Mathur (HDFC Mutual Fund)

Outlook for Unichem EBITDA growth for FY26 and beyond. Partial
Nikhil Mathur: So, Unichem, can see EBITDA growth in FY '26 on a full year basis? Harish Kamath: No. Growth, I don't think it is possible because of Q1, what has happened.

Indicates that Unichem's Q1 performance has significantly impacted its full-year EBITDA growth prospects, suggesting continued challenges.

Asked by Nikhil Mathur (HDFC Mutual Fund)

Ipca standalone US business margin drag and prospects for large-size launches. Direct
See, we have already launched 4 products of Ipca in the US market. Those products, as Mr. Jain said, has a visibility of about $15-$16 million business in the current financial year. Another 4-5 products also should get launched during the current financial year. But immediately after launch, you get market share, then business actually starts. There will be some gap. But going forward, every year, 5-6 Ipca products will go on getting launched in the US market.

Provides specific details on Ipca's US product pipeline and revenue expectations, which is a key growth driver.

Asked by Nikhil Mathur (HDFC Mutual Fund)

2 min read 7 chapters

Detailed narrative

Overall Financial Performance and Margins

Ipca Labs reported a mixed Q1 FY26. Standalone net profit increased by 26% to Rs. 262 crores, while consolidated net profit grew by 18% to Rs. 234 crores. Standalone EBITDA margin improved to 23.82% from 22.22% in Q1 FY25. However, consolidated EBITDA margin saw a marginal decline to 18.39% from 18.52% in Q1 FY25, primarily due to Unichem's performance.

Domestic Business Update

The domestic business grew by approximately 10% in Q1 FY26, maintaining its rank as 16th per IQVIA with a market share increase of 7 bps to 2.08%. While overall growth was positive, the cardiovascular therapy segment underperformed, growing only around 8% due to business reorganization and challenges in recruiting manpower for two new marketing divisions. Management expects a faster recovery in this segment.

Export Business Performance

Export branded formulation business grew by 10% to Rs. 124 crores from Rs. 113 crores in Q1 FY25. The generic business showed stronger growth at 15%, reaching Rs. 326 crores compared to Rs. 283 crores in the prior year. The API business also delivered a 12% growth. Europe and Latin America exports performed well, contributing to the overall 12% export growth.

Unichem's Challenges and Impact

Unichem's consolidated business grew by 9%, but its gross margin declined significantly. This was attributed to market share loss in four major US products, a sharp decline in Asia (Myanmar business fell from Rs. 23 crores to Rs. 8 crores due to import license issues), and a drop in Brazil business (from Rs. 21 crores to Rs. 14 crores). Additionally, Unichem incurred one-time provisions of Rs. 12 crores due to Euro currency fluctuation for an EU penalty and Rs. 10 crores for the closure of its Ireland facility, further impacting profitability.

Subsidiary Performance and Outlook

Onyx Scientific, typically a strong performer, reported a loss of 300,000 sterling pound in Q1 FY26, as business from multinational companies reduced. Pisgah continues to incur losses, though in line with the previous year, with its injectable project expected to be commercially ready by H2 FY26. Management indicated that scaling up subsidiaries, including a new one in Germany, might involve initial losses, with meaningful contributions expected over a 2-3 year period.

Revised Full-Year Guidance

Ipca Labs maintained its FY26 consolidated topline growth guidance at 9%-10%. However, the consolidated EBITDA margin improvement target for FY26 was revised downwards to 75 basis points (bps) from the earlier guidance of 100 bps, primarily due to the underperformance of Unichem. Standalone EBITDA margin is still expected to improve by approximately 1.5% (150 bps) for the full year.

US Market Strategy

For the Ipca standalone US business, management expects around $15-$16 million in revenue for the current financial year from existing deal wins. Four products have already been launched, with another 4-5 products planned for launch this fiscal year. The company aims to launch 5-6 products annually in the US market going forward.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls